Innovation Pharmaceuticals Inc (IPIX)

[Patientspeople]

FirstWord News Release today - Industry News Top Stories
Gilead, Galapagos' experimental drug filgotinib hits main goal of Phase III study in rheumatoid arthritis
Bristol-Myers Squibb reports promising mid-stage data for TYK2 inhibitor in plaque psoriasis
Foamix moves closer to US filing for acne treatment FMX101 after late-stage study success
Takeda to move US headquarters in Deerfield to Massachusetts
Merck KGaA, Pfizer say combination of Bavencio, Inlyta improves PFS versus Sutent in kidney cancer study
Merck & Co. set to seek EU, US approval of Zerbaxa for pneumonia after late-stage study hits goals
In The Know: Analyst answers — Are changes coming to the way we treat MS?

ViewPoints: Bristol-Myers Squibb's oral play in psoriasis slowly coming into focus

In June, Bristol-Myers Squibb began enrolling the first of two pivotal-stage studies for its TYK2 inhibitor BMS 986165 in psoriasis and this week the company will present the Phase II data that supported this decision at the European Academy of Dermatology and Venereology (EADV) meeting.

Key opinion leaders (KOLs) have identified TYK2 inhibitors as a potentially valuable new class of therapy, which administered orally could compete with Celgene's Otezla for the treatment of plaque psoriasis. The stakes are raised further with Bristol-Myers Squibb choosing to select Otezla as an active control arm in one of its recently initiated Phase III studies.